Financial Performance and Subsidiaries Revenue
KEY BUSINESS SEGMENTS
DOMESTIC FORMULATIONS
EXPORT FORMULATIONS
SUBSIDIARIES
NATCO
API BUSINESS
Overview(1)
•
Three key business segments: Oncology,
Specialty Pharma, Cardiology and
Diabetology
Strong brand position in the domestic
oncology
Specialist sales force of nearly 550
personnel and ~1,000 distributors
Strengthened C&D portfolio through
additional 250+ sales force
Launched 11 new products across
oncology and C&D
Targeting 20 product launches a year with
over 12% growth
Strengthening
the gastroenterology,
critical care, oncology and cardio-diabetes
portfolios with expanded geographical,
disease and therapy area coverage
Focused on niche opportunities in the
US, Canada and emerging markets
Integration of Dash Pharmaceuticals
LLC complete and name changed to
Natco Pharma USA LLC
Focus on Para IV and First-to-File
molecules
Strengthening presence in South-east
Asia, MENA and LATAM among other
ROW markets by registering our niche
product portfolio in these countries
•
•
Operations in Brazil, Canada,
Singapore, Australia and
Philippines
generic
Amongst top 10
companies by sales revenue in
Canada. Strong portfolio of
Oncology, cardiovascular and CNS
therapies
In Brazil, continued to increase
our presence in the Oncology and
primary healthcare segments with
strong market share in Everolimus
and Apixaban
Building a strong product portfolio
in Singapore in both Tender and
Private segments
44 active DMFs (1) in the US with niche
products under development
Exports focused on US, Europe and
emerging markets
Oncology APIs and specialty products
Difficult-to-make chemistry with long
synthesis.
Expanding our oligonucleotide portfolio
1.As of March 31, 2023
5View entire presentation